Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

Journal of Urology

Volumn 196, Issue 2, 2016, Pages 382-391

  Heck, Matthias M ^a   Retz, Margitta ^a   D'Alessandria, Calogero ^a   Rauscher, Isabel ^a   Scheidhauer, Klemens ^a   Maurer, Tobias ^a   Storz, Enno ^a   Janssen, Friederike ^a   Schottelius, Margret ^b   Wester, Hans Jürgen ^b   Gschwend, Jürgen E ^a   Schwaiger, Markus ^a   Tauber, Robert ^a   Eiber, Matthias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

castration; glutamate carboxypeptidase II, human; lutetium; neoplasm metastasis; prostatic neoplasms

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; GALLIUM 68; LUTETIUM 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN LU 177; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LIGAND; LUTETIUM; LUTETIUM-177; MEMBRANE ANTIGEN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER GROWTH; CANCER REGRESSION; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DRUG SAFETY; FATIGUE; HUMAN; LOSS OF APPETITE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN SEVERITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; XEROSTOMIA; ADENOCARCINOMA; CASE REPORT; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LIGANDS; LUTETIUM; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84979659039     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.02.2969     Document Type: Article

References (25)

1. 1 Kaatsch, P., Spix, C., Hentschel, S., et al. Cancer in Germany 2009/2010, 9th ed. 2013, Robert Koch Institute and Association of Epidemiologic Cancer Registries in Germany, Berlin.
2. 2 Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer, 49, 2013, 1374.
3. 3 American Cancer Society: Key Statistics for Prostate Cancer. Available at http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed February 6, 2016.
4. 4 Center, M.M., Jemal, A., Lortet-Tieulent, J., et al. International variation in prostate cancer incidence and mortality rates. Eur Urol, 61, 2012, 1079.
5. 5 Silver, D.A., Pellicer, I., Fair, W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res, 3, 1997, 81.
6. 6 Israeli, R.S., Powell, C.T., Corr, J.G., et al. Expression of the prostate-specific membrane antigen. Cancer Res, 54, 1994, 1807.
7. 7 Wright, G.L., Haley, C., Beckett, M.L., et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol, 1, 1995, 18.
8. 8 Wright, G.L., Grob, B.M., Haley, C., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48, 1996, 326.
9. 9 Sweat, S.D., Pacelli, A., Murphy, G.P., et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 52, 1998, 637.
10. 10 Ghosh, A., Heston, W.D.W., Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem, 91, 2004, 528.
11. 11 Lütje, S., Heskamp, S., Cornelissen, A.S., et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics, 5, 2015, 1388.
12. 12 Zechmann, C.M., Afshar-Oromieh, A., Armor, T., et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging, 41, 2014, 1280.
13. 13 Ahmadzadehfar, H., Rahbar, K., Kürpig, S., et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res, 5, 2015, 114.
14. 14 Weineisen, M., Simecek, J., Schottelius, M., et al. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res, 4, 2014, 63.
15. 15 Weineisen, M., Schottelius, M., Simecek, J., et al. 68Ga- and 177Lu-labeled PSMA I&T: Optimization of a PSMA targeted theranostic concept and first proof of concept human studies. J Nucl Med J Nucl Med, 56, 2015, 1169.
16. 16 Bodei, L., Mueller-Brand, J., Baum, R.P., et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 40, 2013, 800.
17. 17 Scher, H.I., Halabi, S., Tannock, I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol, 26, 2008, 1148.
18. 68Gallium-PSMA Positron Emission Tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol, 195, 2016, 1436.
19. 19 Eiber M, Pyka T, Okamoto S et al: 68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients. Presented at annual meeting of European Association of Urology, Munich, Germany, March 11-15, 2016, No. 566.
20. 20 Delker, A., Fendler, W.P., Kratochwil, C., et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging, 43, 2016, 42.
21. 21 Herrmann, K., Bluemel, C., Weineisen, M., et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med, 56, 2015, 855.
22. 22 O'Keefe, D.S., Bacich, D.J., Heston, W.D.W., Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate, 58, 2004, 200.
23. 23 Kwekkeboom, D.J., Krenning, E.P., Lebtahi, R., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology, 90, 2009, 220.
24. 24 Emami, B., Lyman, J., Brown, A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys, 21, 1991, 109.
25. 25 Tagawa, S.T., Milowsky, M.I., Morris, M., et al. Phase II study of 177Lu-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res, 19, 2013, 5182.